ES3059603T3 - A1at for treating acute graft versus host disease after hematopoeitic cell transplantation - Google Patents

A1at for treating acute graft versus host disease after hematopoeitic cell transplantation

Info

Publication number
ES3059603T3
ES3059603T3 ES23209713T ES23209713T ES3059603T3 ES 3059603 T3 ES3059603 T3 ES 3059603T3 ES 23209713 T ES23209713 T ES 23209713T ES 23209713 T ES23209713 T ES 23209713T ES 3059603 T3 ES3059603 T3 ES 3059603T3
Authority
ES
Spain
Prior art keywords
a1at
individual
antitrypsin
procedure
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES23209713T
Other languages
English (en)
Spanish (es)
Inventor
Marc Uknis
Christine Voight
Gautam Baheti
John Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring LLC
Original Assignee
CSL Behring LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring LLC filed Critical CSL Behring LLC
Application granted granted Critical
Publication of ES3059603T3 publication Critical patent/ES3059603T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
ES23209713T 2017-12-01 2018-11-30 A1at for treating acute graft versus host disease after hematopoeitic cell transplantation Active ES3059603T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762593446P 2017-12-01 2017-12-01
US201862729376P 2018-09-10 2018-09-10

Publications (1)

Publication Number Publication Date
ES3059603T3 true ES3059603T3 (en) 2026-03-23

Family

ID=64734181

Family Applications (2)

Application Number Title Priority Date Filing Date
ES23209713T Active ES3059603T3 (en) 2017-12-01 2018-11-30 A1at for treating acute graft versus host disease after hematopoeitic cell transplantation
ES18821851T Active ES2975208T3 (es) 2017-12-01 2018-11-30 A1AT para reducir el riesgo de aparición de la enfermedad aguda de injerto contra huésped tras el trasplante de células hematopoyéticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18821851T Active ES2975208T3 (es) 2017-12-01 2018-11-30 A1AT para reducir el riesgo de aparición de la enfermedad aguda de injerto contra huésped tras el trasplante de células hematopoyéticas

Country Status (13)

Country Link
US (2) US11857610B2 (enExample)
EP (2) EP3716998B1 (enExample)
JP (2) JP2021505545A (enExample)
AU (1) AU2018374285B2 (enExample)
DK (1) DK3716998T3 (enExample)
ES (2) ES3059603T3 (enExample)
FI (1) FI3716998T3 (enExample)
HR (1) HRP20240475T8 (enExample)
HU (1) HUE066011T2 (enExample)
PL (1) PL3716998T3 (enExample)
PT (1) PT3716998T (enExample)
SI (1) SI3716998T1 (enExample)
WO (1) WO2019108865A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021028927A1 (en) * 2019-08-15 2021-02-18 Kamada Ltd Combination of alpha-1-antitrypsin and steroids and uses therefor
EP4408175A4 (en) * 2021-10-01 2025-08-06 Univ Colorado Regents COMPOSITIONS AND METHODS FOR REDUCED TOXICITY IN TRANSPLANTATION USING JANUS KINASE (JAK) INHIBITORS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2654446C (en) 2005-06-07 2014-02-25 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
US9457070B2 (en) * 2005-06-07 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
CN101341254A (zh) * 2005-12-24 2009-01-07 蒂加斯克乳制品研究中心 反-10，顺-12十八碳二烯酸的生产方法
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
KR20130115086A (ko) * 2010-05-17 2013-10-21 세빅스 인코포레이티드 페길화된 c-펩티드
WO2012178102A2 (en) * 2011-06-24 2012-12-27 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
KR102231139B1 (ko) 2011-06-28 2021-03-24 인히브릭스, 인크. 세르핀 융합 폴리펩타이드 및 이의 이용 방법
US10400029B2 (en) * 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CA2896951A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
EP2978442B1 (en) 2013-03-29 2020-03-18 The Regents of the University of Colorado, a body corporate Alpha 1 antitrypsin of use for preparing a subject for transplant
WO2017117558A1 (en) * 2015-12-31 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications

Also Published As

Publication number Publication date
ES2975208T3 (es) 2024-07-04
WO2019108865A1 (en) 2019-06-06
JP2021505545A (ja) 2021-02-18
EP3716998A1 (en) 2020-10-07
HRP20240475T8 (hr) 2024-08-02
PT3716998T (pt) 2024-04-09
AU2018374285A1 (en) 2020-07-02
PL3716998T3 (pl) 2024-06-24
SI3716998T1 (sl) 2024-05-31
HRP20240475T1 (hr) 2024-07-05
US20240238395A1 (en) 2024-07-18
US11857610B2 (en) 2024-01-02
EP4321220A3 (en) 2024-03-20
EP4321220A2 (en) 2024-02-14
JP2024001191A (ja) 2024-01-09
EP3716998B1 (en) 2024-01-10
AU2018374285B2 (en) 2024-06-27
HUE066011T2 (hu) 2024-07-28
US20210008182A1 (en) 2021-01-14
DK3716998T3 (da) 2024-04-02
FI3716998T3 (fi) 2024-04-16
EP4321220B1 (en) 2025-10-29

Similar Documents

Publication Publication Date Title
TWI880888B (zh) 抗體－藥物結合物之製劑及其冷凍乾燥方法
ES2954311T3 (es) Reemplazo de un preacondicionamiento citotóxico antes de una inmunoterapia celular
TWI800341B (zh) 抗cd38抗體之皮下調配物及其用途
JP6920230B2 (ja) アルファ−１アンチトリプシン融合ポリペプチド、それをコードする核酸構築体、及びそれらの組成物
UA127771C2 (uk) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЯКА МІСТИТЬ ЗЛИТИЙ ПРОТЕЇН РЕЦЕПТОРА TGF-<font face="Symbol">b, </font>ТА ЇЇ ЗАСТОСУВАННЯ
CA2993478A1 (en) Compositions and methods for immunomodulation
BR112019018043A2 (pt) método de tratamento de câncer, e, conjugado de anticorpo-fármaco
WO2020102728A1 (en) Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
US20120269806A1 (en) Methods of inducing tolerance
BR112020020277A2 (pt) Anticorpos anti-cd40 para uso na prevenção de rejeição de enxerto
JP2023531251A (ja) 抗ｃｄ２抗体
US20240238395A1 (en) Methods for Reducing Risk of Onset of Acute Graft Versus Host Disease After Hematopoeitic Cell Transplantation
WO2021129775A1 (zh) 抗ctla-4单克隆抗体及其制备方法与应用
CN117159703A (zh) 含抗lag-3抗体的药物组合物及其用途
US11512141B2 (en) Fibrinogen-like protein 2 (FGL2) monoclonal antibodies and their use in cancer detection and treatment
JP2021527056A (ja) 移植片対宿主病及び粘膜炎の予防及び治療のためのｃｄ２４の使用方法
ES2869909T3 (es) Composiciones y métodos para la modificación del receptor de la proteína tensioactiva A
KR20220129548A (ko) 생물제약 조성물 및 관련 방법
EP4100045A1 (en) Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
US20250228942A1 (en) Methods for activation and expansion of engineered natural killer cells and combinations with antibodies
HK40106704A (en) A1at for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation
CA3195260A1 (en) Fusion proteins for the treatment of disease
AU2015201676A1 (en) Anti-C5a antibodies and methods for using the antibodies
ES2682523B1 (es) Uso de moduladores de la funcion de cd69 para la movilizacion y proliferacion de precursores hematopoyeticos
WO2025207763A1 (en) Method and composition for inducing tolerance of transplanted organ or tissue